Association of large joint involvement at the start of biological disease‐modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study.

MLA

Shirasugi, Iku, et al. “Association of Large Joint Involvement at the Start of Biological Disease‐modifying Antirheumatic Drugs and Janus Kinase Inhibitors with Disease Activity and Drug Retention in Patients with Rheumatoid Arthritis: The ANSWER Cohort Study.” International Journal of Rheumatic Diseases, vol. 27, no. 3, Mar. 2024, pp. 1–9. EBSCOhost, https://doi.org/10.1111/1756-185X.15097.

APA

Shirasugi, I., Onishi, A., Nishimura, K., Yamamoto, W., Murakami, K., Onizawa, H., Maeda, Y., Ebina, K., Son, Y., Amuro, H., Katayama, M., Hara, R., Nagai, K., Hiramatsu, Y., Hashimoto, M., Okano, T., Maeda, T., Hayashi, S., Sendo, S., & Jinno, S. (2024). Association of large joint involvement at the start of biological disease‐modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study. International Journal of Rheumatic Diseases, 27(3), 1–9. https://doi.org/10.1111/1756-185X.15097

Chicago

Shirasugi, Iku, Akira Onishi, Keisuke Nishimura, Wataru Yamamoto, Kosaku Murakami, Hideo Onizawa, Yuichi Maeda, et al. 2024. “Association of Large Joint Involvement at the Start of Biological Disease‐modifying Antirheumatic Drugs and Janus Kinase Inhibitors with Disease Activity and Drug Retention in Patients with Rheumatoid Arthritis: The ANSWER Cohort Study.” International Journal of Rheumatic Diseases 27 (3): 1–9. doi:10.1111/1756-185X.15097.